Compositions and methods for biological remodeling with frozen particle compositions
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G06F-019/00
A61K-035/12
C07K-016/28
A61K-031/00
A61K-038/38
A61K-009/00
A61K-035/32
A61K-038/48
A61K-031/70
A61K-035/16
A61K-051/12
A61K-035/28
A61K-031/7088
A61K-009/16
A61K-009/08
A61K-033/00
A61K-035/34
A61K-009/19
A61K-041/00
A61K-045/06
C07K-016/30
A61K-031/337
A61K-009/14
A61K-009/70
A61K-039/00
A61K-038/00
출원번호
US-0384218
(2009-03-31)
등록번호
US-8788212
(2014-07-22)
발명자
/ 주소
Boyden, Edward S.
Cook, Daniel B.
Hyde, Roderick A.
Leuthardt, Eric C.
Myhrvold, Nathan P.
Sweeney, Elizabeth A.
Wood, Jr., Lowell L.
출원인 / 주소
The Invention Science Fund I, LLC
인용정보
피인용 횟수 :
2인용 특허 :
142
초록▼
Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particula
Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.
대표청구항▼
1. A system comprising: circuitry for comparing information regarding at least one parameter for at least partially constructing or at least partially reconstructing at least one biological tissue of a subject before administration of one or more frozen particle compositions to the biological tissue
1. A system comprising: circuitry for comparing information regarding at least one parameter for at least partially constructing or at least partially reconstructing at least one biological tissue of a subject before administration of one or more frozen particle compositions to the biological tissue and deposition of at least part of the one or more frozen particle compositions including at least one tracer agent, and information regarding at least one clinical outcome following receipt by the at least one subject of one or more frozen particle compositions;circuitry for detecting the at least one tracer agent;circuitry for communicating real-time feedback control of the amount of the one or more frozen particle compositions including at least one tracer agent administered;circuitry for administering the one or more frozen particle compositions for partially constructing or reconstructing the at least one biological tissue based on detection of the at least one tracer agent;circuitry for providing output information based on the comparison; andcircuitry for evaluating the at least one biological tissue for one or more of deposition of the one or more frozen particle compositions, tissue formation, or tissue growth. 2. The system of claim 1, further including circuitry for determining at least one statistical correlation. 3. The system of claim 1, further including circuitry for counting the occurrence of at least one clinical outcome. 4. The system of claim 1, wherein the information regarding at least one parameter of at least partially constructing or at least partially reconstructing at least one biological tissue of a subject includes information regarding quantity of cells or tissue at least partially constructed or at least partially reconstructed. 5. The system of claim 1, wherein the information regarding at least one parameter of at least partially constructing or at least partially reconstructing at least one biological tissue of a subject includes information regarding at least one cellular or tissue source. 6. The system of claim 1, wherein the information regarding at least one parameter of at least partially constructing or at least partially reconstructing at least one biological tissue of a subject includes information regarding at least one abnormal cellular or tissue source. 7. The system of claim 1, wherein the information regarding at least one parameter of at least partially constructing or at least partially reconstructing at least one biological tissue of a subject includes information regarding at least one type of cell or tissue. 8. The system of claim 1, wherein the at least one frozen particle composition includes at least one adhesive agent, abrasive, reinforcement agent, therapeutic agent, biological remodeling agent, or explosive material. 9. The system of claim 1, wherein the information regarding at least one parameter of at least partially constructing or at least partially reconstructing at least one biological tissue of a subject includes information regarding at least one dimension of at least one agent deposited. 10. The system of claim 1, wherein the information regarding at least one parameter of at least partially constructing or at least partially reconstructing at least one biological tissue of at least one subject includes information regarding at least one dimension of at least one depth, width, or breadth of cellular, tissue, or other material removal or destruction. 11. The system of claim 1, wherein the information regarding at least one clinical outcome following receipt by the at least one subject of one or more frozen particle compositions includes information regarding two or more subjects with one or more common attributes. 12. The system of claim 11, wherein the one or more common attributes include one or more of genetic attributes, mental attributes, proteomic attributes, phenotypic attributes, or psychological attributes. 13. The system of claim 11, wherein the one or more common attributes include one or more of height, weight, medical diagnosis, familial background, results on one or more medical tests, ethnic background, body mass index, age, presence or absence of at least one disease or condition, species, ethnicity, race, allergies, gender, thickness of tissue, blood vessel condition, hair or fur condition, skin condition, tissue condition, muscle condition, organ condition, nerve condition, brain condition, presence or absence of at least one biological, chemical, or therapeutic agent in the subject, pregnancy status, lactation status, genetic profile, proteomic profile, partial or whole genetic sequence, partial or whole proteomic sequence, medical condition, medical history, or blood condition. 14. The system of claim 1, wherein the output information includes at least one of a response signal, comparison code, comparison plot, diagnostic code, treatment code, test code, code indicative of at least one treatment received, code indicative of at least one prescribed treatment step, code indicative of at least one vaccination administered, code indicative of at least one therapeutic agent administered, code indicative of at least one diagnostic agent administered, code indicative of at least one interaction of an administered agent and at least one biological or chemical agent in the subject; a code indicative of at least one dispersion or location of at least one administered agent; code indicative of at least one detection material administered; code indicative of the depth of penetration of an administered agent, code indicative of the depth of deposition of an administered agent, or a code indicative of the condition of at least one location of an administered frozen particle composition. 15. The system of claim 1, wherein receipt by the at least one subject of one or more frozen particle compositions is pursuant to at least one clinical trial. 16. The system of claim 1, further including circuitry for creating at least one inclusion criterion and at least one exclusion criterion for a clinical trial involving the one or more frozen particle compositions. 17. The system of claim 1, further including circuitry for suggesting the inclusion of one or more of the at least one subject in at least one clinical trial. 18. The system of claim 1, further including circuitry for suggesting the exclusion of one or more of the at least one subject in at least one clinical trial. 19. The system of claim 1, further including circuitry for predicting at least one clinical outcome involving at least one second subject, wherein the at least one second subject is a plurality of people; and segregating subject identifiers associated with the plurality of people in reference to the predicted at least one clinical outcome. 20. The system of claim 19, further including circuitry for determining the eligibility of the at least one second subject for the at least one clinical trial. 21. The system of claim 1, wherein the one or more frozen particle compositions include one or more frozen particles including at least one of hydrogen oxide, nitrogen, oxygen, air, helium, neon, argon, xenon, chlorine, bromine, carbon dioxide, acetone, ethyl acetate, dimethyl sulfoxide, dimethyl formamide, dioxane, tetrahydrofuran, acetronitrile, acetic acid, n-butanol, isopropanol, n-propanol, hexamethylphosphorotriamide, perfluorohydrocarbon, methanol, ethanol, tert-butyl alcohol, formic acid, hydrogen fluoride, ammonia, benzene, carbon tetrachloride, acetonitrile, hexane, dichloromethane, methylene chloride, carboxylic acid, saline, standard saline citrate, methane, toluene, chloroform, polyethylene glycol, acetic acid, Ringer's solution, lactated Ringer's solution, Hartmann's solution, acetated Ringer's solution, phosphate buffered solution, TRIS-buffered saline solution, Hank's balanced salt solution, Earle's balanced salt solution, standard saline citrate, HEPES-buffered saline, dextrose, glucose, methane, or diethyl ether. 22. The system of claim 1, wherein the frozen particle compositions include at least one biological remodeling agent that includes one or more of calcium phosphate, albumin, cytokine, pegylated cytokine, bone, cartilage, globulin, fibrin, thrombin, glutaraldehyde-crosslinked pericardium, hide powder, hyaluronic acid, hydroxylapatite, keratin, ligament, nitinol, nucleic acid polymers, polyethylene, polylethylene glycol, polyethylene glycol diacrylate, polyethylene terephthalate fiber, polyglycol, polylactate, polytetrafluoroethylene, polylactic acid, polyglycolic acid, polycaprolactone, PURAMATRIX™ self-assembly peptide hydrogel fibers, linear aliphatic polyester, tendon, fibrinogen, hyaluronate, chitin, chitosan, methylcellulose, alginate, hyaluronic acid, agarose, cellulose, polyaldehyde gluronate, Factor XIII, Factor XII, silk, nylon, collagen, silicone, polyurethane, ceramic powder, elastin, pectin, wax, glycosaminoglycan, poly(α-hydroxyacid), selectin, glutaraldehyde, hydrophobic non-glycosylated protein, hydrogel, peptide hydrogel, or gelatin. 23. The system of claim 1, wherein the comparing information includes at least one of image processing, predicting, modeling, or simulation of constructing or reconstructing the at least one biological tissue. 24. A system comprising: circuitry for predicting a clinical outcome of one or more frozen particle compositions treatment for at least one first subject, includingcircuitry for determining a similarity or a dissimilarity in information regarding at least one parameter for at least partially constructing or at least partially reconstructing at least one biological tissue of at least one first subject before administration of one or more frozen particle compositions including at least one tracer agent to the at least one first subject and deposition of at least part of the one or more frozen particle compositions, with information regarding at least one parameter of at least partially constructing or at least partially reconstructing at least one biological tissue of at least one second subject, wherein the at least one second subject attained a clinical outcome following receipt of one or more frozen particle compositions;circuitry for detecting the at least one tracer agent;circuitry for communicating real-time feedback control of the administration of the one or more frozen particle compositions including at least one tracer agent;andcircuitry for providing output information including a code indicative of the depth of penetration of a delivered composition, or a code indicative of the dispersion or location of at least one delivered composition based on the real-time feedback. 25. The system of claim 24, wherein the information regarding at least one parameter of at least partially constructing or at least partially reconstructing at least one biological tissue of at least second subject includes information regarding quantity of cells or tissue at least partially constructed or at least partially reconstructed. 26. The system of claim 24, wherein the information regarding at least one parameter of at least partially constructing or at least partially reconstructing at least one biological tissue of at least one first subject includes information regarding at least one cellular or tissue source. 27. The system of claim 24, wherein the information regarding at least one parameter of at least partially constructing or at least partially reconstructing at least one biological tissue of at least one first subject includes information regarding at least one abnormal cellular or tissue source. 28. The system of claim 24, wherein the information regarding at least one parameter of at least partially constructing or at least partially reconstructing at least one biological tissue of at least one first subject includes information regarding at least one type of cell or tissue. 29. The system of claim 24, wherein the information regarding at least one parameter of at least partially constructing or at least partially reconstructing at least one biological tissue of at least one second subject includes information regarding at least one type of cell or tissue. 30. The system of claim 24, wherein the one or more frozen particle compositions include at least one agent including one or more of an adhesive agent, abrasive, reinforcement agent, therapeutic agent, biological remodeling agent, or explosive material. 31. The system of claim 24, wherein the information regarding at least one parameter of at least partially constructing or at least partially reconstructing at least one biological tissue of at least one first subject includes information regarding at least one dimension of at least one depth, width, or breadth of cellular, tissue, or other material removal or destruction. 32. The system of claim 24, wherein the information regarding at least one clinical outcome following receipt by the at least one second subject of one or more frozen particle compositions includes information regarding two or more subjects with one or more common attributes. 33. The system of claim 32, wherein the one or more common attributes include one or more of genetic attributes, mental attributes, proteomic attributes, phenotypic attributes, or psychological attributes. 34. The system of claim 32, wherein the one or more common attributes include one or more of height, weight, medical diagnosis, familial background, results on one or more medical tests, ethnic background, body mass index, age, presence or absence of at least one disease or condition, species, ethnicity, race, allergies, gender, thickness of tissue, blood vessel condition, hair or fur condition, skin condition, tissue condition, muscle condition, organ condition, nerve condition, brain condition, presence or absence of at least one biological, chemical, or therapeutic agent in the subject, pregnancy status, lactation status, genetic profile, proteomic profile, partial or whole genetic sequence, partial or whole proteomic sequence, medical condition, medical history, or blood condition. 35. The system of claim 24, wherein the output information includes at least one of a response signal, comparison code, comparison plot, diagnostic code, treatment code, test code, code indicative of at least one treatment received, code indicative of at least one prescribed treatment step, code indicative of at least one vaccination administered, code indicative of at least one therapeutic agent administered, code indicative of at least one diagnostic agent administered, code indicative of at least one interaction of an administered agent and at least one biological or chemical agent in the subject; a code indicative of at least one dispersion or location of at least one administered agent; code indicative of at least one detection material administered; code indicative of the depth of penetration of an administered agent, code indicative of the depth of deposition of an administered agent, or a code indicative of the condition of at least one location of an administered frozen particle composition. 36. The system of claim 24, wherein receipt by the at least one second subject of one or more frozen particle compositions is pursuant to at least one clinical trial. 37. The system of claim 24, further including circuitry for determining at least one correlation before the administration of the one or more frozen particle compositions to the at least one first subject. 38. The system of claim 24, further including circuitry for creating at least one inclusion criterion and at least one exclusion criterion for a clinical trial involving the one or more frozen particle compositions. 39. The system of claim 24, further including circuitry for suggesting the inclusion of one or more of the at least one first subject in at least one clinical trial. 40. The system of claim 24, further including circuitry for suggesting the exclusion of one or more of the at least one first subject in at least one clinical trial. 41. The system of claim 24, further including circuitry for predicting at least one clinical outcome involving the at least one second subject, wherein the at least one second subject is a plurality of people; and means for segregating subject identifiers associated with the plurality of people in reference to the predicted at least one clinical outcome. 42. The system of claim 24, wherein the one or more frozen particle compositions include one or more frozen particles including at least one of hydrogen oxide, nitrogen, oxygen, air, helium, neon, argon, xenon, chlorine, bromine, carbon dioxide, acetone, ethyl acetate, dimethyl sulfoxide, dimethyl formamide, dioxane, tetrahydrofuran, acetronitrile, acetic acid, n-butanol, isopropanol, n-propanol, hexamethylphosphorotriamide, perfluorohydrocarbon, methanol, ethanol, tert-butyl alcohol, formic acid, hydrogen fluoride, ammonia, benzene, carbon tetrachloride, acetonitrile, hexane, dichloromethane, methylene chloride, carboxylic acid, saline, standard saline citrate, methane, toluene, chloroform, polyethylene glycol, acetic acid, Ringer's solution, lactated Ringer's solution, Hartmann's solution, acetated Ringer's solution, phosphate buffered solution, TRIS-buffered saline solution, Hank's balanced salt solution, Earle's balanced salt solution, standard saline citrate, HEPES-buffered saline, dextrose, glucose, methane, or diethyl ether. 43. The system of claim 24, wherein the one or more frozen particle compositions include one or more of an adhesive agent, therapeutic agent, reinforcement agent, abrasive, explosive material, or biological remodeling agent. 44. The system of claim 43, wherein the at least one biological remodeling agent includes one or more of calcium phosphate, albumin, cytokine, pegylated cytokine, bone, cartilage, globulin, fibrin, thrombin, glutaraldehyde-crosslinked pericardium, hide powder, hyaluronic acid, hydroxylapatite, keratin, ligament, nitinol, nucleic acid polymers, polyethylene, polylethylene glycol, polyethylene glycol diacrylate, polyethylene terephthalate fiber, polyglycol, polylactate, polytetrafluoroethylene, polylactic acid, polyglycolic acid, polycaprolactone, PURAMATRIX™ self-assembly peptide hydrogel fibers, linear aliphatic polyester, tendon, fibrinogen, hyaluronate, chitin, chitosan, methylcellulose, alginate, hyaluronic acid, agarose, cellulose, polyaldehyde gluronate, Factor XIII, Factor XII, silk, nylon, collagen, silicone, polyurethane, ceramic powder, elastin, pectin, wax, glycosaminoglycan, poly(α-hydroxyacid), selectin, glutaraldehyde, hydrophobic non-glycosylated protein, hydrogel, peptide hydrogel, or gelatin. 45. A system comprising: circuitry for comparing information regarding at least one parameter for at least partially constructing or at least partially reconstructing at least one biological tissue of a subject before administration of one or more frozen particle compositions to the biological tissue and deposition of at least part of the one or more frozen particle compositions including at least one tracer agent, and information regarding at least one clinical outcome following receipt by the at least one subject of one or more frozen particle compositions;circuitry for detecting the at least one tracer agent;circuitry for communicating real-time feedback control for administration of the one or more frozen particle compositions;circuitry for administering the one or more frozen particle compositions for partially constructing or reconstructing the at least one biological tissue;circuitry for displaying the results of the comparison; andcircuitry for evaluating the at least one biological tissue for one or more of deposition of the one or more frozen particle compositions, tissue formation, or tissue growth. 46. the system of claim 45, wherein the comparing information includes at least one of image processing, predicting, modeling, or simulation of constructing or reconstructing the at least one biological tissue.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (142)
Phillips William T. (San Antonio TX) Klipper Robert W. (San Antonio TX) Timmons James H. (Tacoma WA) Rudolph Alan S. (Bowie MD), 99m TC labeled liposomes.
Smits Georges (Gijzegem-Aalst BEX) Daenekindt Luc (Gijzegem-Aalst BEX) Booten Karl (Geetbets BEX), Agglomerated composition, process for producing it and food products containing the said composition.
Armstrong Jay (1543 Weymouth Cir. ; Apt. 109 Westlake OH 44145) Becker James R. (6272 Mills Creek La. North Ridgeville OH 44039), Blast cleaning system.
Topalian Harry H. (Dover DE) Wyss Clement R. (Lewes DE) Kenyon Ralph E. (Dover DE) Dec Anthony F. (Dover DE), Frozen aerated ready-to-eat gelatin composition.
Brinegar Chris (587 Locksley Rd. Boulder Creek CA 95006) Gilmore James (6385 Camino Verde Dr. San Jose CA 95119) Johnson Michael (6385 Camino Verde Dr. San Jose CA 95119) Walker Nigel (5385 Broadway , Ice-mediated introduction of substances into biological material.
Thomas Dag Horn ; Sandra Marchese Johnson, Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction.
Rahman Aquilur (Gaithersburg MD) Rafaeloff Rafael (Tel-Aviv MD ILX) Husain Syed R. (Gaithersburg MD), Liposome encapsulated taxol and a method of using the same.
Weaver, James C.; Anderson, R. Rox; Herndon, Terry O; Gowrishankar, T. R.; Gift, Elizabeth A.; Gonzalez, Salvador, Localized molecular and ionic transport to and from tissues.
Poulsen, Jens Ulrik; Christensen, Lars Hofmann; Aasmul, S.o slashed.ren, Method and a system for assisting a user in a medical self treatment, said self treatment comprising a plurality of actions.
Power Wendy ; Reed Michael A. ; Frustaci Dominick J. ; Larocque Gerald ; Marchetti Brenda, Method and apparatus for determining quantity of liquid in a container and/or lack of motion thereof.
Frohlich, Hans; Gebhardt, Sabine; Trampusch, Berthold, Method and device for generating a two-phase gas-particle jet, in particular containing CO2 dry ice particles.
Cates Michael C. (Solana Beach CA) Hamm Richard R. (San Diego CA) Lewis Michael W. (Wichita KS) Schmitz Wayne N. (St. Louis MO), Method and system for removing a coating from a substrate using radiant energy and a particle stream.
Costantino Henry R. ; Jaworowicz Warren E. ; Tracy Mark A. ; Beganski Christopher P., Method of producing sub-micron particles of biologically active agents and uses thereof.
Cummins Thomas J. (Rochester NY) Ekeze Tobias D. (Rochester NY), Methods of extracting nucleic acids and PCR amplification without using a proteolytic enzyme.
Rhim Won-Kyu (Pasadena CA) Hyson Michael T. (Glendale CA) Chung Sang-Kun (Diamond Bar CA) Colvin Michael S. (Malibu CA) Chang Manchium (Los Angeles CA), Monodisperse, polymeric microspheres produced by irradiation of slowly thawing frozen drops.
Shih, Hong; Leonte, Oana M.; Daugherty, John E.; Huang, Tuochuan; Goldspring, Gregory J.; May, Michael C., On-line chamber cleaning using dry ice blasting.
Clark ; Jr. William G. (Murrysville PA) Herald John J. (Monroeville PA) Liaw Peter K. (Knoxville TN), Pressurized ferrofluid paint removal system using an electromagnet and eddy current encircling coil to adjust weight per.
Fages Jacques,FRX ; Marty Alain,FRX ; Combes Didier,FRX ; Condoret Jean-Stephane,FRX, Process for treating bone tissue and corresponding implantable biomaterials.
Clauss Steven L. (Manville NJ) Pastel Michael J. (Highland Mills NY) Zawadzki Rainer K. (Wuhan CNX), Stable porfimer sodium compositions and methods for their manufacture.
Boyden, Edward S.; Cook, Daniel B.; Hyde, Roderick A.; Leuthardt, Eric C.; Myhrvold, Nathan P.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L., Systems, devices, and methods for making or administering frozen particles.
Santa Cruz Cathy D. ; Deniston-Korgol Christine L. ; Baugh Barbara I. ; Baugh Alexandria D. ; Baugh Roger D., Weather-proof wrist, forearm, and elbow protectors.
Dean ; Jr. Robert C. (Norwich VT) Silver Frederick H. (Long Valley NJ) Berg Richard A. (Lambertville NJ) Phillips Philip G. (Norwich VT) Runstadler ; Jr. Peter W. (Hanover NH), Weighted collagen microsponge for immobilizing bioactive material.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.